Drug target interaction of tubulin-binding drugs in cancer therapy.

about

N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines: a novel class of antitumor agents targeting the colchicine site on tubulin.Target Based Designing of Anthracenone Derivatives as Tubulin Polymerization Inhibiting Agents: 3D QSAR and Docking Approach.

P2860

Q37164102-24AF5B0E-B008-48FA-B022-AC167F1D000A Q41984117-B9E7E06B-BA72-498F-91B0-2C6032FE4B8A

P2860

Drug target interaction of tubulin-binding drugs in cancer therapy.

Item

http://www.wikidata.org/entity/Q36636645

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Drug target interaction of tubulin-binding drugs in cancer therapy.

@ast

Drug target interaction of tubulin-binding drugs in cancer therapy.

@en

type

Item

label

Drug target interaction of tubulin-binding drugs in cancer therapy.

@ast

Drug target interaction of tubulin-binding drugs in cancer therapy.

@en

prefLabel

Drug target interaction of tubulin-binding drugs in cancer therapy.

@ast

Drug target interaction of tubulin-binding drugs in cancer therapy.

@en

P1476

Drug target interaction of tubulin-binding drugs in cancer therapy.

@en

P2093

Sannu Ann Thomas

http://www.w3.org/2001/XMLSchema#string

Suparna Sengupta

http://www.w3.org/2001/XMLSchema#string

P2860

Microtubules as a target for anticancer drugs

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends

Docetaxel in patients with anthracycline-resistant advanced breast cancer.

Novel aspects of natural and modified vinca alkaloids.

Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.

A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer.

Mechanisms of Taxol resistance related to microtubules.

Cell cycle control and cancer.

Antitumor properties of podophyllotoxin and related compounds.

P304

1433-1447

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.6.10.1433

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17069528

http://www.w3.org/2001/XMLSchema#string

Drug target interaction of tubulin-binding drugs in cancer therapy.

about

P2860

P2860

Drug target interaction of tubulin-binding drugs in cancer therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698